Riding on patent office win, Novartis takes Gilenya generics fight to court

20th July 2018 Uncategorised 0

Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to extend that win to the legal system, hoping to block copycats from entering the U.S. until 2027.

More: Riding on patent office win, Novartis takes Gilenya generics fight to court
Source: fierce